Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA

Cyndeo Wealth Partners LLC bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,715 shares of the company’s stock, valued at approximately $101,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its holdings in Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after purchasing an additional 1,655 shares during the last quarter. Harbour Investments Inc. increased its holdings in Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after purchasing an additional 2,264 shares during the last quarter. Quantbot Technologies LP increased its holdings in Intellia Therapeutics by 846.4% in the 1st quarter. Quantbot Technologies LP now owns 6,663 shares of the company’s stock valued at $47,000 after purchasing an additional 5,959 shares during the last quarter. GAMMA Investing LLC increased its holdings in Intellia Therapeutics by 1,961.2% in the 1st quarter. GAMMA Investing LLC now owns 7,544 shares of the company’s stock valued at $540,000 after purchasing an additional 7,178 shares during the last quarter. Finally, 49 Wealth Management LLC acquired a new stake in Intellia Therapeutics in the 1st quarter valued at approximately $74,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 9,364 shares of company stock valued at $137,674. Insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on NTLA shares. Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Wells Fargo & Company reiterated an “overweight” rating and issued a $45.00 target price (down previously from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday. HC Wainwright boosted their price target on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Finally, Chardan Capital dropped their price target on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Thirteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $27.95.

Intellia Therapeutics Trading Down 3.7%

Intellia Therapeutics stock opened at $24.52 on Friday. The stock has a market cap of $2.63 billion, a P/E ratio of -5.23 and a beta of 2.37. The company has a fifty day simple moving average of $13.97 and a 200-day simple moving average of $10.81. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $26.99.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to analysts’ expectations of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The company’s revenue for the quarter was up 104.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.52) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.